| Biomarker ID | 1187 |
| PMID | 23918943 |
| Year | 2013 |
| Biomarker | Methylation Status of C1orf114 (as continous variable) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Lower Methylation in Patients with Longer Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: Univariate: [4.74 (95% CI: 3.00 to 7.48)]; Multivariate: [3.10 (95% CI: 1.89 to 5.09)]Cohort 2: Univariate: [5.37 (95% CI: 1.99 to 14.5)]; Multivariate: [0.74 (95% CI: 1.17 to 9.12)] |
| Effect on Pathways | Pathways include: CACNA1D knockdown 96h PC3, CHEK2 knockdown 96h A549, NR2C1 knockdown 96h HCC515 , CAMK2D knockdown 96h PC3, SNRK knockdown 96h PC3 |
| Experiment | Biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.892 |
| Accuracy | NA |
| Level Of Significance | P < 0.001 |
| Method Used | quantitative methylation specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | C1orf114 |